Silent Killer Condition: £1 Pill to Prevent Deaths
Summary of the Article: SGLT2 Inhibitors & Diabetes/Kidney Disease
This article focuses on the benefits of SGLT2 inhibitor medications for people with diabetes, and increasingly, for those with kidney disease, even without diabetes. Here’s a breakdown of the key points:
Significant Benefits: SGLT2 inhibitors can reduce the risk of needing dialysis or a kidney transplant by 25%. They also offer protection against heart problems. Early Intervention is Key: The drugs are most effective when started soon after a diabetes diagnosis – preventing kidney disease from developing in the first place, rather than just slowing its progression in advanced stages.
New NHS Guidance: The NHS now recommends GPs offer SGLT2 inhibitors immediately after a diabetes diagnosis,alongside metformin. Patients with heart disease should receive SGLT2 inhibitors, metformin, and a GLP-1 injection (like Ozempic).
Triple Therapy: Combining an SGLT2 inhibitor, metformin, and a GLP-1 drug provides the best protection against kidney disease.
Safety & Side Effects: The drugs are generally safe. The most common side effect is genital thrush, wich is easily preventable and treatable with over-the-counter creams.
Implementation Challenges: Despite the new guidance, there’s concern that many GPs are unaware of these medications, leading to patients missing out on possibly life-saving treatment. It will take about a year for the guidance to be fully implemented.
All SGLT2 Inhibitors are Similar: Research suggests all available SGLT2 inhibitors are equally effective,so patients don’t need to request a specific brand.
Call to Action: Patients who believe they might be eligible should discuss SGLT2 inhibitors with their GP.
In essence, the article highlights a promising development in diabetes and kidney disease management, but emphasizes the need for wider awareness and implementation among healthcare professionals to ensure patients benefit from these advancements.